Efficacy of Vardenafil and Sildenafil in Facilitating Penile Erection in an Animal Model

ABSTRACT Vardenafil and sildenafil are potent and specific phosphodiesterase type 5 (PDE 5) inhibitors. In human penile cavernosal smooth muscle cells, we have previously shown that vardenafil has a lower biochemical inhibition constant (Ki) than sildenafil. In this study, we compared the efficacy o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of andrology 2002-05, Vol.23 (3), p.332-337
Main Authors: Choi, Seong, O'Connell, Luke, Min, Kweonsik, Kim, Noel N, Munarriz, Ricardo, Goldstein, Irwin, Bischoff, Erwin, Traish, Abdulmaged M
Format: Article
Language:English
Subjects:
Anesthesia
Animals
Biological and medical sciences
Blood Pressure - drug effects
Dose-Response Relationship, Drug
Electric Stimulation
Genital system. Reproduction
Hypogastric Plexus - physiology
Imidazoles - pharmacology
Injections, Intravenous
intracavernosal pressure
Male
Medical sciences
Models, Animal
Pelvic nerve‐mediated erection
Penile Erection - drug effects
Penis - innervation
Penis - physiology
Pharmacology. Drug treatments
Piperazines - pharmacology
Pressure
Purines
Rabbits
Sildenafil Citrate
Sulfones
Triazines
Vardenafil Dihydrochloride
Vasodilator Agents - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Vardenafil and sildenafil are potent and specific phosphodiesterase type 5 (PDE 5) inhibitors. In human penile cavernosal smooth muscle cells, we have previously shown that vardenafil has a lower biochemical inhibition constant (Ki) than sildenafil. In this study, we compared the efficacy of vardenafil and sildenafil in facilitating penile erection in a rabbit model. Penile erections were elicited by submaximal (2.5 or 6 Hz) pelvic nerve stimulation (PNS) repeated every 5 minutes for 30 minutes with or without intravenous (IV) administration of vardenafil (1–30 μg/kg) or sildenafil (10–30 μg/kg). Erectile response was assessed by continuously recording intracavernosal pressure (ICP) and systemic arterial pressure (SAP). All data were expressed as a ratio of ICP:SAP. IV administration of either PDE 5 inhibitor facilitated PNS‐induced erection and increased ICP:SAP in a dose‐dependent manner, reaching peak response at approximately 5 minutes. However, the threshold dose at which facilitation of erection occurred was lower for vardenafil (3 μg/kg) than for sildenafil (10 μg/kg). At the 10‐μg/kg dose (IV), the response duration was significantly greater with vardenafil (169 ± 23 seconds) than with sildenafil (137 ± 31 seconds). Direct intracavernosal (IC) injection of 1–30 μg/kg vardenafil or sildenafil also caused dose‐dependent increases in ICP: SAP in the absence of PNS. Response durations increased in a dose‐dependent manner and lasted more than 5 times that of IV drug administration coupled with PNS. Irrespective of the route of administration (IC or IV), at equivalent doses, vardenafil was significantly more efficacious than sildenafil in facilitating pelvic nerve‐mediated penile erection and in eliciting erection in the absence of PNS. The increases in ICPs occurred more quickly, were of larger magnitude, and were sustained for longer durations for vardenafil than for sildenafil. On the basis of the biochemical data and physiological responses from this study, further clinical evaluation of vardenafil as treatment for erectile dysfunction is warranted.
ISSN:0196-3635
1939-4640
DOI:10.1002/j.1939-4640.2002.tb02239.x